Molnlycke has published data from a new study showing the benefits of using its Mepilex Lite dressings to prevent radiation-induced erythema among patients undergoing breast cancer therapy.

Results from a trial involving 24 women were presented last week at a European Wound Management Association meeting, comparing the effectiveness of Molnlycke's product to standard aqueous creams.

It was found that Mepilex Lite performed significantly better than the creams in reducing erythema levels, while the test subjects also stated that they found the dressings to be more comfortable.

Thanks to this treatment, the patients were able to minimise the amount of pain they experienced, allowing them to resume wearing normal clothing.

Magnus Enerback, global category manager at Molnlycke, said: "We are truly proud to be able to provide customers with products that help their patients to a better quality of life."

Last month, the company pledged its support to the World Health Organization's new drive to combat the spread of antimicrobial resistance, highlighting the role played by topical dressings such as Mepilex in accomplishing this.